Moderna claimed that the decision, issued by top vaccine regulator Vinay Prasad, was “inconsistent” with prior FDA ...

The potentially $4.4 billion deal is Madrigal’s second with a China-based biotech and hands the company six preclinical RNA interference medicines for the common liver condition.

Shares of Evommune nearly doubled on data suggesting it has a potential threat to Dupixent. Elsewhere, a closely watched narcolepsy drug got an FDA decision date and investors scrutinized Upstream’s ...

Kailera CEO Ron Renaud claimed the weight loss effects and safety profile observed in the study suggest its therapy could ...

CagriSema’s blood sugar and weight reductions exceeded the company’s blockbuster Wegovy, yet the drug might still struggle to ...

Lilly could pay Innovent Biologics up to $9 billion in a new alliance. Elsewhere, Roche tried to assuage investor concerns about its new multiple sclerosis drug and Roivant shares surged.

AstraZeneca’s investment will “span the value chain” of drug research and development and comes amid a prolonged surge in ...

Select products from Pfizer, Eli Lilly and others will be sold at a discount, although the lower costs won’t be felt by many ...

Shares fell as much as 6% in after-hours trading, a decline one analyst guessed may be because Yeztugo’s trajectory isn’t ...

The agency’s program will be open to pharmaceutical facilities that align with “national priorities.” Elsewhere, a ...

Data integrity is key to the success of any cell therapy program. CDMOs can implement robust data management systems for ...

A massive overhaul of staffing and review processes have left the agency appearing heavily driven by the Trump administration ...